Mesenchymal stem cells as a therapeutic approach to glomerular diseases: benefits and risks  by Kunter, Uta et al.
Mesenchymal stem cells as a therapeutic approach
to glomerular diseases: benefits and risks
Uta Kunter1, Song Rong1, Marcus J. Moeller1 and Ju¨rgen Floege1
1Department of Nephrology and Immunology, Medical Faculty, RWTH University of Aachen, Aachen, Germany
Most studies using adult stem cells (ASCs) and progenitor
cells as potential therapeutics for kidney disorders have been
conducted in models of acute kidney injury, where the
damage mainly affects the tubulointerstitium. The results are
promising, whereas the underlying mechanisms are still
being discussed controversially. Glomerular diseases have
not received as much attention. Likely reasons include the
often insidious onset, rendering the choice of optimal
treatment timing difficult, and the fact that chronic diseases
may require long-term therapy. In this mini review, we
summarize current strategies in adult stem cell-based
therapies for glomerular diseases. In addition, we focus on
possible side effects of stem cell administration that have
been reported recently, that is, profibrotic actions and
maldifferentiation of mesenchymal stem cells.
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DIFFERENT APPROACHES TO STEM CELL-BASED RENAL
THERAPIES
Several investigators have described distinct types of appa-
rently endogenous, resident renal stem/progenitor cells.1–11
Others have investigated strategies to mobilize exogenous
adult stem cells (ASCs) and enhance their engraftment
in renal disease.12–17 Another approach is to isolate ASCs
from extrarenal tissues, expand them in vitro, and inject
them into the recipient, an approach that will be further
elucidated in this review. Finally, given recent evidence that
beneficial effects of ASCs are mostly paracrine,18–25 some
investigators have tested whether the administration of a cell-
free ‘cocktail’ of factors secreted by ASCs, that is, cell culture
supernatants, might be equally effective as whole ASCs.26,27
One of the mechanisms herein has been suggested to be
secreted microparticles enriched in pre-microRNAs, facilitat-
ing miRNA-mediated intercellular communication.28
BONE MARROW IS A RESERVOIR OF REGENERATIVE CELLS
FOR RENAL REPAIR
Bone marrow-derived (stem) cells contribute to cell turnover
and repair in various tissues, including the kidneys.29,30 For
example, differentiation of mouse and rat bone marrow cells
into glomerular cell phenotypes was described in normal and
diseased glomeruli.31–34 Cell culture experiments confirmed
the ability of bone marrow cells to convert into mesangial-
like cells on administration of platelet-derived growth
factor-BB in the presence of type IV collagen.35 Two recent
studies in chronic renal failure obtained promising results
in ameliorating glomerulosclerosis and proteinuria by
administering lineage-negative bone marrow cells 15 days
after 5/6 nephrectomy36 or dedifferentiated fat cells with
characteristics similar to mesenchymal stem cells (MSCs) in
tenascin-C knockout mice with habu snake venom-induced
nephritis.37
Of the three major marrow-derived lineages, MSCs hold
special promise for renal repair because nephrons are largely
of mesenchymal origin. In a model of cisplatin-induced acute
kidney injury (AKI), MSCs were more efficacious than
hematopoietic stem cells in repairing damage.38 In athymic
nude mice with glomerular injury, injected human MSCs
localized to glomeruli and differentiated into mesangial-like
cells.39 One recent publication reports on the protective
effects of MSCs on coculture with adriamycin-treated
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podocytes in vitro (reduction of apoptosis), but injection of
MSCs in vivo did not show regenerative effects in the
adriamycin model of nephropathy.40
CHARACTERIZATION OF MSCs AND THEIR MAIN PROPERTIES
MSCs, or ‘multipotent mesenchymal stromal cell(s)’,41 have
to fulfil consensus criteria regarding their phenotype and
biological behavior.42 Although undisputable criteria defin-
ing MSCs are still not available,43,44 the emerging data render
them strong candidates for human therapies. Potentially
more specific markers for human MSCs have been
described.45–47
MSCs can be cultured without significant ethical concerns
from adult bone marrow aspirates, adipose tissue, or umbi-
lical cord blood,48 and can be expanded under inexpensive
conditions in vitro. Their phenotypic stability is superior to
that of embryonic stem cells, although cytogenetic aberra-
tions in mouse MSCs after several passages in vitro and
sarcoma formation of transduced MSCs in recipient mice
have been observed.49 Others have found human MSCs to
be very resistant against cytogenetic aberrations, probably
because of their increased senescence and thus reduced
proliferation rate under culture conditions.50
Another appealing aspect is that syngeneic MSCs can be
obtained from a patient before a calculated medical risk, that
is, major surgery, and later be re-administered in the case of
organ failure (that is, AKI). In experimental AKI, MSC
injection shortly after disease induction ameliorated the
course of the disease.21,25,26,38,51–55 Even allogeneic transplan-
tation of MSCs seems feasible given their tolerance-inducing
effects and their ability to escape T-cell recognition (reviewed
in McTaggart and Atkinson56). Several preclinical and clinical
studies using MSCs are currently ongoing (reviewed in
Giordano et al.57).
Older studies on MSCs focussed mainly on their ability to
adopt non-mesenchymal phenotypes, that is, neural pre-
cursors and cardiomyocytes. However, methods used to
verify transdifferentiation of MSCs (and ASCs in general)
into other phenotypes in vivo are technically problematic and
prone to misinterpretation.6,25,58–60 In addition, naturally
occurring, but rare, fusion events of ASCs with injured
kidney cells have been observed.61 More recent studies
suggest that MSCs exert most of their effects through
paracrine mechanisms.21,62–64
MSC INJECTION ENHANCES GLOMERULAR HEALING IN A
MODEL OF ACUTE GLOMERULONEPHRITIS
Rat MSCs injected directly into a renal artery can accelerate
recovery from mesangiolytic damage and prevent transient
AKI in a rat model of mesangioproliferative glomerulone-
phritis.63 In contrast, MSC injection into a tail vein was
ineffective, which may be due to MSCs losing their homing
capacity after in vitro culture.65 In inbred Lewis rats, anti-
Thy1.1 nephritis follows an aggravated course with transient
AKI. Again, AKI and mesangiolysis were ameliorated by
syngeneic MSCs. MSCs largely failed to differentiate into
endothelial, mesangial, or monocyte/macrophage-like cells.
Rather, we found that MSCs secreted high amounts of
vascular endothelial growth factor and transforming growth
factor-b1, suggesting that MSCs likely exerted beneficial
effects in glomeruli by paracrine effects.
TRANSPLANTATION OF FULL BONE MARROW OR MSCs CAN
AMELIORATE A MODEL OF CHRONIC GLOMERULONEPHRITIS
Anti-Thy 1.1 nephritis induced in uninephrectomized rats
results in progressive renal failure.66 In this model, bone
marrow contributes mainly to glomerular endothelial cell
regeneration in the weeks following disease induction.67 In
addition, infused bone marrow prevented death of the
nephritic animals.68 Using the same progressive anti-Thy 1.1
nephritis, we investigated the long-term effects of early
administration of syngeneic MSCs into the renal artery in
chronic renal failure.69 Again, MSCs ameliorated early AKI
and reduced glomerular adhesions. After 50 days, proteinuria
had progressed in controls, but stayed low in MSC-treated
animals. Renal function on day 60 in the MSC group was
better than that in medium controls, more glomeruli had
recovered from the initial injury and tubulointerstitial
fibrosis was reduced.
MALDIFFERENTIATION OF MSCs DURING LONG-TERM
FOLLOW-UP OF CHRONIC GLOMERULONEPHRITIS
In the above study,69 at day 60, about 20% of the glomeruli of
MSC rats contained adipocytes apparently derived from the
injected MSCs using various lines of evidence.69 Both adipo-
cytes and their pronounced surrounding fibrosis severely
distorted the normal glomerular morphology (Figure 1).
Despite the maldifferentiation of glomerular MSCs into
adipocytes and the fibrotic response surrounding them,
renal function was better preserved than in controls. This is
likely the consequence of two counteracting effects of MSC
treatment; that is, improved early preservation of glomeruli
during mesangiolysis on one hand versus maldifferentiation
and fibrosis on the other hand. However, the morpho-
logical aspect of glomeruli containing adipocytes strongly
suggests that these glomeruli should exhibit a marked
functional impairment and ultimately develop global
glomerulosclerosis.
Other unwanted stem cell-associated phenomena include
findings in murine lungs, where injected MSCs were trapped,
and, similar to our findings in glomeruli, formed ‘cysts’ with
adjacent collagen deposition, resulting in severe lung
damage.70 Mouse MSC transplantation into infarcted hearts
resulted in extensive bone formation in the myocardium.71
Earlier, less well-documented reports of such unwanted
phenomena include bone marrow transplantation, leading to
the formation of new bone in ‘inappropriate’ locations.72
At present, our novel observation of ‘orthodox MSC
differentiation’ in an ‘unorthodox location’ raises consider-
able concerns about the safety of MSC-based cell thera-
pies. Resolving these concerns will require extensive tests
to evaluate how to prevent such unwanted differentiation.
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So far, no unwanted differentiation of MSCs has been
observed in animals with AKI at 3 months after systemic
MSC injection.54 However, in that study, the MSCs did not
localize to the kidney, but rather migrated to the bone
marrow.
Nevertheless, a recent case report on a patient with severe
lupus nephritis, who had received percutaneous intrarenal
injections of autologous peripheral stem cell preparations in
a private clinic, seems to confirm the possibility of stem cell
maldifferentiation in humans: The cell injections apparently
led to formation of solid renal (and extrarenal) masses
showing angiomyeloproliferative and myeloproliferative
components.73
MSCs IN GENETIC RENAL DISEASES: EXPERIENCES FROM
ALPORT MICE
When mice deficient of the collagen a3(IV)-chain
(‘Alport mice’) were lethally irradiated and then transplanted
with allogeneic unfractionated bone marrow from LacZ-mice
with normal collagen production, or from another Alport
mouse,74,75 only the normal allogeneic bone marrow
improved renal function and diminished fibrosis. LacZ-
positive cells constituted about 10% of the glomerular cells
and were found in podocyte and mesangial cell locations. In a
third study,64 weekly injections of MSCs in the Alport mice
prevented loss of peritubular capillaries and reduced inter-
stitial fibrosis. However, irradiation alone also increases
survival of Alport mice,76 which has sparked a debate on the
role of stem cells in the above studies. Interestingly, even
transfusion of unfractionated wild-type blood into non-
irradiated Alport mice improved both renal phenotype and
survival, as shown by LeBleu and Kalluri.77
In another study, human fetal MSCs were transplanted
intrauterinally into mice deficient for collagen type I a2,
a condition that induces abnormal progressive collagen
deposition in glomeruli.78 Renal engraftment of fetal human
MSCs was only about 1% of total kidney cells, but it reduced
the abnormal collagen type I deposition in 4- to 12-week-old
transgenic mice.78
MSCs CAN INFLUENCE FIBROTIC PROCESSES
We provided first evidence for both a pro- and anti-fibrotic
role of MSCs in renal disease.63,69 Others have described that
bone marrow-derived mesangial cell progenitors from ROP
Os/þ mice, a model of spontaneous glomerulosclerosis, can
transmit glomerulosclerosis when transplanted into con-
genicþ /þ mice.29 In another study, bone marrow-derived
cells differentiated into renal tubulointerstitial myofibroblasts
after ischemia/reperfusion injury.79 There are also a number
of studies documenting the acquisition of a myofibroblast-
like MSC phenotype in chronically injured livers,80 chronic
heart allograft rejection,81 and ovarian cancer.82
OTHER ASCs WITHIN THE GLOMERULUS
Recently, it was noted that human parietal epithelial cells
express the stem cell markers CD24, CD133, CD106, and
stem cell-specific transcription factors.7 On injection into
severe combined immunodeficiency mice, these cells, termed
‘adult parietal epithelial multipotent progenitors’, were
capable of ameliorating AKI and differentiated into tubuli.
In recent work, we have investigated whether parietal cells
have the capability to differentiate into podocytes. Using a
novel transgenic mouse model, parietal epithelial cells were
genetically tagged. With this approach, we could provide the
first definitive clues that in young developing mice, parietal
cells migrate onto the capillary tuft and differentiate into
podocytes83 (Figure 1). Studies using human adult parietal
epithelial multipotent progenitors showed similar findings
in adult mice.84 Understanding the regulation of this




Figure 1 | Evidence for intraglomerular maldifferentiation of mesenchymal stem cells (MSCs) in Lewis rats with anti-Thy1.1
nephritis on day 60 after disease induction, day 58 after injection of 2 106 cells into the renal artery and recruitment of parietal
epithelial cells during development. (a) Periodic acid-Schiff staining exhibited ‘vacuolar’ changes (*) that were positive for triglycerides
in Oil Red O staining (not shown). (b) Staining for collagen type IV shows an intense fibrotic area (arrow) around the ‘vacuoles’. Original
magnification:  400. (c) Recruitment of podocytes from parietal cells in juvenile mice Cre recombination was induced in newborn
triple transgenic PEC-rtTA/LC1/R26R mice by administration of doxycyclin for 3 days. After 6 weeks, the mice were culled and the glomeruli
were double-stained with an enzymatic X-gal (blue)/eosin (red) staining to visualize genetically tagged cells. As expected, parietal cells
lining the inner side of Bowman’s capsule were genetically tagged (black arrowheads). Close to the vascular pole, genetically tagged
transitional cells could be identified (arrow with tails). On the capillary convolute, a genetically tagged podocyte can be seen (arrow),
which was recruited from parietal cells.
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glomerular diseases. Nevertheless, in this context, it appeared
as if progenitor cells once again showed unwanted effects:
Smeets et al.11 could demonstrate a contribution of glome-
rular progenitor cells to hyperplastic lesions in crescentic
glomerulonephritis.
In addition to adult parietal epithelial multipotent
progenitors, extraglomerular mesangial precursor cells can
invade the glomerulus after damage from the hilar pole juxta-
glomerular region and contribute to mesangial restitution.85
Whether these cells represent ASCs is currently unknown.
CONCLUSION
MSCs have now been firmly established as sources for
protective factors mediating paracrine effects,21,62–64 support-
ing the evolving concept of protection rather than differ-
entiation.18 Unwanted side effects include the potentially
proangiogenic role of MSCs in tumor formation and adop-
tion of unwanted phenotypes (‘maldifferentiation’),69,71,73
which need to be investigated more systematically in the
future. Alternatively, instead of administering cultured MSCs,
enhanced recruitment of endogenous MSCs might help to
avoid maldifferentiation.71 Once MSC trafficking is more
completely understood, other strategies aiming at increasing/
inducing homing of endogenous MSCs to nephritic glomer-
uli should be assessed.86 Another approach is to manipulate
MSCs in vitro. For example, hypoxic preconditioning
augments the angiogenic potential of cultured MSCs through
increased vascular endothelial growth factor expression.87
Despite the above concerns, the high potential of MSCs
for solid organ and glomerular repair, in particular, cannot
be denied.
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